- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04174443
The Efficacy and Safety of Pulsed Radiofrequency Combined With Continuous Radiofrequency for the Trigeminal Neuralgia (PRFCRF)
July 20, 2023 updated by: Fang Luo, Beijing Tiantan Hospital
The Efficacy and Safety of the Application of Pulsed Radiofrequency, Combined With Low-temperature Continuous Radiofrequency, to the Gasserian Ganglion for the Treatment of Primary Trigeminal Neuralgia
Trigeminal neuralgia is a very painful condition, and radiofrequency therapy is reserved for patients who are resistant or intolerant to pharmacological therapy.
Continuous radiofrequency and pulsed radiofrequency both have advantages and disadvantages.
Recently, studies have found that pulsed radiofrequency combined with low-temperature (<65 °C) continuous radiofrequency increases the efficacy of the treatment, without leading to a significant increase in complications caused by nerve lesions.
However, these reports have some limitations.
The investigators plan to conduct a randomized, controlled study to compare the efficacy of applying high-voltage pulsed radiofrequency, with and without low-temperature continuous radiofrequency, to the gasserian ganglion for the treatment of trigeminal neuralgia.
The primary outcome will be the effectiveness of the treatment after 12 months which is the percentage of participants with a modified Barrow Neurological Institute Pain Intensity Score between I-III.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
146
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fang Luo, MD
- Phone Number: +8613611326978
- Email: 13611326978@163.com
Study Contact Backup
- Name: Hao Ren, MD
- Phone Number: +8618701229893
- Email: renh2014@mail.ccmu.edu.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100070
- Beijing Tiantan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed with trigeminal neuralgia according to the International Classification of Headache Disorders, 3rd Edition criteria.
- Aged 18-75 years (inclusive), no sex limitation.
- Suffering from severe trigeminal neuralgia that cannot be alleviated effectively using conservative medical therapy such as carbamazepine, oxcarbazepine.
- Numeric rating scale score≥7 before the procedure.
- Agreed to sign the informed consent form.
Exclusion Criteria:
- Secondary trigeminal neuralgia such as trigeminal neuralgia attributed to a space-occupying lesion or multiple sclerosis.
- Infection at the puncture site.
- A history of psychiatric disease.
- Disorder indicated in the results of routine blood tests, hepatic function, renal function, coagulation function, electrocardiogram, or chest X-ray.
- Serious systemic diseases such as uncontrolled hypertension or diabetes, and cardiac dysfunction (II-III of the New York Heart Association classification).
- A history of abuse of narcotics.
- A history of receiving continuous radiofrequency to the gasserian ganglion or peripheral branches; glycerol rhizolysis; balloon compression; gamma knife; or any other neuroablative treatments.
- A history of receiving microvascular decompression.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pulsed radiofrequency + Continuous radiofrequency
|
2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.
|
Active Comparator: Pulsed radiofrequency
|
2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of participants with a modified Barrow Neurological Institute Pain Intensity Score of I-III
Time Frame: Twelve months after the procedure
|
The modified Barrow Neurological Institute Pain Intensity Score (I: No pain, off medications; II: Occasional pain, off medications; IIIa: No pain, continued use of medications; IIIb: Pain persists, but adequately controlled with medications; IV: Pain not adequately controlled with medications; V: No relief) will be used to evaluate the efficacy of the treatment.
Twelve months after the procedure, participants with Barrow Neurological Institute scores of I-III will be defined as having received effective treatment.
The primary outcome will be the effectiveness of the treatment after 12 months.
|
Twelve months after the procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The modified Barrow Neurological Institute Pain Intensity Score
Time Frame: On day 1; at 1 and 2 weeks; and after 1, 2, 3, 6, and 12 months following the procedure
|
The modified Barrow Neurological Institute Pain Intensity Score (I: No pain, off medications; II: Occasional pain, off medications; IIIa: No pain, continued use of medications; IIIb: Pain persists, but adequately controlled with medications; IV: Pain not adequately controlled with medications; V: No relief) will be used to evaluate the efficacy of the treatment.
|
On day 1; at 1 and 2 weeks; and after 1, 2, 3, 6, and 12 months following the procedure
|
Numeric rating scale
Time Frame: On day 1; at 1 and 2 weeks; and after 1, 2, 3, 6, and 12 months following the procedure
|
Pain was assessed after surgery by a numerical rating scale (0 indicates no pain, 10 indicates the most severe pain imaginable).
|
On day 1; at 1 and 2 weeks; and after 1, 2, 3, 6, and 12 months following the procedure
|
Dose of carbamazepine or oxcarbazepine
Time Frame: On day 1; at 1 and 2 weeks; and after 1, 2, 3, 6, and 12 months following the procedure
|
Dose of carbamazepine or oxcarbazepine per day (mg/day)
|
On day 1; at 1 and 2 weeks; and after 1, 2, 3, 6, and 12 months following the procedure
|
Patient satisfaction scores on the 5-point Likert scale
Time Frame: After 1, 6 and 12 months following the procedure
|
1: poor, 2: fair, 3: good, 4: very good, 5: excellent
|
After 1, 6 and 12 months following the procedure
|
The World Health Organization Quality of Life (WHOQOL)-BREF
Time Frame: After 1, 6 and 12 months following the procedure
|
Quality of life will be measured using the World Health Organisation QoL-BREF (WHOQOL-BREF) questionnaire.
The WHOQOL-BREF is a abbreviated version of the WHOQOL-100 assessment.
WHOQOL-BREF is a self-report questionnaire that contains 26 items and addresses 4 QOL domains: physical health (7 items), psychological health (6 items), social relationships (3 items) and environment (8 items).
Two other items measure overall QOL and general health.
Each domain's mean score can range between 4 and 20 and a higher score indicates a higher quality of life.
The mean score of items within each domain is used to calculate the domain score.
A transformation method converts domain scores to a 0-100 scale.
|
After 1, 6 and 12 months following the procedure
|
Numbness
Time Frame: On day 1; at 1 and 2 weeks; and after 1, 2, 3, 6, and 12 months following the procedure
|
The Barrow Neurological Institute facial numbness scores (I: No facial numbness; II: Mild facial numbness, not bothersome; III: Facial Numbness, somewhat bothersome; IV: Facial numbness, very bothersome) will be used to evaluate the facial numbness.
|
On day 1; at 1 and 2 weeks; and after 1, 2, 3, 6, and 12 months following the procedure
|
Number of participants with anesthesia dolorosa
Time Frame: Within 12 months of the procedure
|
The participant's facial sensation decreased, accompanied by pain
|
Within 12 months of the procedure
|
Number of participants with masticator weakness
Time Frame: Within 12 months of the procedure
|
Occlusal dysfunction or a lower degree of masseter muscle fullness on one side when biting hard.
|
Within 12 months of the procedure
|
Number of participants with corneal anesthesia
Time Frame: Within 12 months of the procedure
|
When touching the sclera with a cotton swab hair does not cause the eyelids to close quickly.
|
Within 12 months of the procedure
|
Number of participants with keratitis
Time Frame: Within 12 months of the procedure
|
Eye dryness and pain, photophobia, lacrimation, excess mucus and other conditions diagnosed as keratitis by an ophthalmologist
|
Within 12 months of the procedure
|
Number of participants with adverse reactions
Time Frame: Within two weeks of the procedure
|
Nausea, vomiting, and facial hematoma during and after the procedure; headache, dizziness, and cerebrospinal fluid leakage occurring within two weeks of the procedure.
|
Within two weeks of the procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Fang Luo, MD, Beijing Tiantan Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 2, 2020
Primary Completion (Actual)
October 26, 2022
Study Completion (Estimated)
October 26, 2023
Study Registration Dates
First Submitted
November 17, 2019
First Submitted That Met QC Criteria
November 20, 2019
First Posted (Actual)
November 22, 2019
Study Record Updates
Last Update Posted (Estimated)
July 24, 2023
Last Update Submitted That Met QC Criteria
July 20, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY-2019-266-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trigeminal Neuralgia
-
Klinikum Klagenfurt am WörtherseeUniversity of KlagenfurtCompletedGlossopharyngeal Neuralgia | Trigeminal Neuralgia, Idiopathic | Postherpetic; Neuralgia, Trigeminal (Etiology) | Atypical Facial PainAustria
-
Beijing Tiantan HospitalCompletedTrigeminal Neuralgia, SecondaryChina
-
University of FloridaFacial Pain Research FoundationCompleted
-
BiogenCompletedTrigeminal Neuralgia (TN) | Other Neuropathic PainUnited States
-
Shifa Clinical Research CenterCompletedTrigeminal Neuralgia, Idiopathic
-
Ziekenhuis Oost-LimburgCompletedTrigeminal Neuralgia (TN)Belgium
-
Vanderbilt University Medical CenterCompletedTrigeminal NeuralgiaUnited States
-
Seoul National UniversityRecruitingFacial Pain | Cluster Headache | Trigeminal Neuralgia | Postherpetic NeuralgiaKorea, Republic of
-
Beijing Tiantan HospitalBeijing Friendship Hospital; Beijing Ditan HospitalCompletedIdiopathic Trigeminal NeuralgiaChina
-
Danish Headache CenterRecruitingTrigeminal NeuralgiaDenmark
Clinical Trials on High-voltage pulsed radiofrequency
-
Hospital Son LlatzerRecruiting
-
Assiut UniversityNot yet recruiting
-
Basaksehir Cam & Sakura Şehir HospitalCompletedPain, Chronic | Facet Joint Pain | Pain SyndromeTurkey
-
Cukurova UniversityCompleted
-
Assiut UniversityUnknownTrigeminal Neuralgia | Pain, Neuropathic
-
Universitair Ziekenhuis BrusselUnknownChronic Disease | Lumbar RadiculopathyBelgium
-
Assiut UniversityRecruitingNeuralgia | Failed Back Surgery SyndromeEgypt
-
Cairo UniversityCompleted
-
Hospital Universitario La FeUnknown